SG Americas Securities’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $158K | Sell |
9,288
-8,968
| -49% | -$148K | ﹤0.01% | 2894 |
|
|
2026
Q1 | $296K | Buy |
18,256
+3,747
| +26% | +$66.3K | ﹤0.01% | 2462 |
|
|
2025
Q4 | $271K | Buy |
14,509
+7,571
| +109% | +$126K | ﹤0.01% | 2804 |
|
|
2025
Q3 | $101K | Buy |
+6,938
| New | +$87.7K | ﹤0.01% | 3081 |
|
|
2025
Q2 | – | Sell |
-21,557
| Closed | -$193K | – | 3575 |
|
|
2025
Q1 | $193K | Buy |
21,557
+2,355
| +12% | +$21.9K | ﹤0.01% | 2559 |
|
|
2024
Q4 | $181K | Buy |
19,202
+3,349
| +21% | +$30.5K | ﹤0.01% | 2248 |
|
|
2024
Q3 | $128K | Sell |
15,853
-146,535
| -90% | -$1.27M | ﹤0.01% | 2858 |
|
|
2024
Q2 | $1.38M | Sell |
162,388
-47,178
| -23% | -$426K | 0.01% | 1143 |
|
|
2024
Q1 | $1.88M | Buy |
209,566
+12,460
| +6% | +$115K | 0.01% | 888 |
|
|
2023
Q4 | $2.21M | Sell |
197,106
-55,503
| -22% | -$559K | 0.02% | 637 |
|
|
2023
Q3 | $2.18M | Buy |
252,609
+101,475
| +67% | +$980K | 0.02% | 670 |
|
|
2023
Q2 | $1.56M | Buy |
151,134
+121,126
| +404% | +$1.34M | 0.01% | 856 |
|
|
2023
Q1 | $326K | Buy |
30,008
+14,601
| +95% | +$154K | ﹤0.01% | 2067 |
|
|
2022
Q4 | $173K | Sell |
15,407
-11,858
| -43% | -$125K | ﹤0.01% | 2302 |
|
|
2022
Q3 | $276K | Buy |
27,265
+9,567
| +54% | +$89.6K | ﹤0.01% | 2058 |
|
|
2022
Q2 | $160K | Buy |
+17,698
| New | +$163K | ﹤0.01% | 2823 |
|
|
2022
Q1 | – | Sell |
-21,711
| Closed | -$240K | – | 3416 |
|
|
2021
Q4 | $240K | Sell |
21,711
-17,257
| -44% | -$150K | ﹤0.01% | 2574 |
|
|
2021
Q3 | $288K | Buy |
38,968
+30,926
| +385% | +$346K | ﹤0.01% | 2980 |
|
|
2021
Q2 | $117K | Buy |
+8,042
| New | +$151K | ﹤0.01% | 2578 |
|
|
2021
Q1 | – | Sell |
-42,230
| Closed | -$750K | – | 3549 |
|
|
2020
Q4 | $750K | Buy |
+42,230
| New | +$758K | ﹤0.01% | 1707 |
|
|
2020
Q3 | – | Sell |
-16,643
| Closed | -$349K | – | 3422 |
|
|
2020
Q2 | $349K | Sell |
16,643
-11,535
| -41% | -$296K | ﹤0.01% | 2407 |
|
|
2020
Q1 | $651K | Buy |
28,178
+22,143
| +367% | +$554K | 0.01% | 1617 |
|
|
2019
Q4 | $156K | Buy |
+6,035
| New | +$117K | ﹤0.01% | 2663 |
|
|
2019
Q2 | – | Sell |
-6,890
| Closed | -$156K | – | 3406 |
|
|
2019
Q1 | $156K | Buy |
+6,890
| New | +$175K | ﹤0.01% | 2744 |
|
|
2018
Q2 | – | Sell |
-5,347
| Closed | -$130K | – | 3543 |
|
|
2018
Q1 | $130K | Buy |
+5,347
| New | +$147K | ﹤0.01% | 2743 |
|
|
2017
Q4 | – | Sell |
-9,061
| Closed | -$310K | – | 3614 |
|
|
2017
Q3 | $310K | Buy |
9,061
+3,130
| +53% | +$102K | ﹤0.01% | 2202 |
|
|
2017
Q2 | $236K | Buy |
5,931
+443
| +8% | +$17K | ﹤0.01% | 2304 |
|
|
2017
Q1 | $202K | Sell |
5,488
-16,022
| -74% | -$512K | ﹤0.01% | 2431 |
|
|
2016
Q4 | $686K | Buy |
+21,510
| New | +$667K | 0.01% | 1514 |
|
Other funds holding TBPH
MAP
WAM
NM
ICM
SG Americas Securities's TBPH Position: Q2 2026 in Review
SG Americas Securities reduced its Theravance Biopharma (TBPH) stake by 49% in Q2 2026, selling an estimated $148K and leaving 9,288 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #2894.
SG Americas Securities first reported a position in TBPH in Q4 2016 and has held it in 29 quarters since. The position peaked at $2.21M in Q4 2023. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.
- SG Americas Securities held 9,288 shares of Theravance Biopharma worth $158K as of Q2 2026.
- SG Americas Securities sold 8,968 Theravance Biopharma shares in Q2 2026, an estimated $148K.
- Theravance Biopharma made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2894 holding.
- SG Americas Securities first reported a position in Theravance Biopharma in Q4 2016 and has held it in 29 quarters since.
- SG Americas Securities's Theravance Biopharma position peaked at $2.21M in Q4 2023.
- 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.